QR kód

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identify inhibitors that may enhance the anti-tumor acti...

Celý popis

Uloženo v:
Hlavní autoři: Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI AG 2021-06-01
Edice:Biomedicines
Témata:
neratinib
HER2-positive breast cancer
triple-negative breast cancer
RNAi screening
synergistic effect
On-line přístup:https://www.mdpi.com/2227-9059/9/7/740
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky